RT Journal Article
SR Electronic
T1 Early Anakinra Treatment for COVID-19 Guided by Urokinase Plasminogen Receptor
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.16.21257283
DO 10.1101/2021.05.16.21257283
A1 Kyriazopoulou, Evdoxia
A1 Poulakou, Garyfallia
A1 Milionis, Haralampos
A1 Metallidis, Simeon
A1 Adamis, Georgios
A1 Tsiakos, Konstantinos
A1 Fragkou, Archontoula
A1 Rapti, Aggeliki
A1 Damoulari, Christina
A1 Fantoni, Massimo
A1 Kalomenidis, Ioannis
A1 Chrysos, Georgios
A1 Angheben, Andrea
A1 Kainis, Ilias
A1 Alexiou, Zoi
A1 Castelli, Francesco
A1 Serino, Francesco Saverio
A1 Bakakos, Petros
A1 Nicastri, Emanuele
A1 Tzavara, Vassiliki
A1 Kostis, Evangelos
A1 Dagna, Lorenzo
A1 Koufargyris, Panagiotis
A1 Dimakou, Katerina
A1 Tzatzagou, Glykeria
A1 Chini, Maria
A1 Bassetti, Matteo
A1 Katrini, Konstantina
A1 Kotsis, Vasileios
A1 Tsoukalas, George
A1 Selmi, Carlo
A1 Bliziotis, Ioannis
A1 Samarkos, Michael
A1 Doumas, Michael
A1 Ktena, Sofia
A1 Masgala, Aikaterini
A1 Papanikolaou, Ilias
A1 Argyraki, Aikaterini
A1 Cardellino, Chiara Simona
A1 Katsigianni, Eleni-Ioanna
A1 Giannitsioti, Efthymia
A1 Cingolani, Antonella
A1 Akinosoglou, Karolina
A1 Liatsis-Douvitsas, Orestis
A1 Symbardi, Styliani
A1 Mouktaroudi, Maria
A1 Ippolito, Giuseppe
A1 Florou, Eleni
A1 Kotsaki, Antigone
A1 Netea, Mihai G.
A1 Eugen-Olsen, Jesper
A1 Kyprianou, Miltiades
A1 Panagopoulos, Periklis
A1 Dalekos, George N.
A1 Giamarellos-Bourboulis, Evangelos J.
YR 2021
UL http://medrxiv.org/content/early/2021/05/18/2021.05.16.21257283.abstract
AB Background In a previous open-label trial, early anakinra treatment guided by elevated soluble urokinase plasminogen activator receptor (suPAR) prevented progression of COVID-19 pneumonia into respiratory failure.Methods In the SAVE-MORE multicenter trial, 594 hospitalized patients with moderate and severe COVID-19 pneumonia and plasma suPAR 6 ng/ml or more and receiving standard-of-care were 1:2 randomized to subcutaneous treatment with placebo or 100 mg anakinra once daily for 10 days. The primary endpoint was the overall clinical status of the 11-point World Health Organization ordinal Clinical Progression Scale (WHO-CPS) at day 28. The changes of the WHO-CPS and of the sequential organ failure assessment (SOFA) score were the main secondary endpoints.Results Anakinra-treated patients were distributed to lower strata of WHO-CPS by day 28 (adjusted odds ratio-OR 0.36; 95%CI 0.26-0.50; P<0.001); anakinra protected from severe disease or death (6 or more points of WHO-CPS) (OR: 0.46; P: 0.010). The median absolute decrease of WHO-CPS in the placebo and anakinra groups from baseline was 3 and 4 points respectively at day 28 (OR 0.40; P<0.0001); and 2 and 3 points at day 14 (OR 0.63; P: 0.003); the absolute decrease of SOFA score was 0 and 1 points (OR 0.63; P: 0.004). 28-day mortality decreased (hazard ratio: 0.45; P: 0.045). Hospital stay was shorter.Conclusions Early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in moderate and severe COVID-19 pneumonia.(Sponsored by the Hellenic Institute for the Study of Sepsis ClinicalTrials.gov identifier, NCT04680949)Competing Interest StatementG. Poulakou has received independent educational grants from Pfizer, MSD, Angelini, and Biorad. H. Milionis reports receiving honoraria, consulting fees and non-financial support from healthcare companies, including Amgen, Angelini, Bayer, Mylan, MSD, Pfizer, and Servier. L. Dagna had received consultation honoraria from SOBI. M. Bassetti has received funds for research grants and/or advisor/consultant and/or speaker/chairman from Angelini, Astellas, Bayer, Biomerieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, Roche, Shionogi and Nabriva. M. G. Netea is supported by an ERC Advanced Grant (#833247) and a Spinoza grant of the Netherlands Organization for Scientific Research. He has also received independent educational grants from TTxD, GSK and ViiV HealthCare. J. Eugen-Olsen is a co-founder, shareholder and CSO of ViroGates, Denmark, and named inventor on patients on suPAR owned by Copenhagen University Hospital Hvidovre, Denmark. P. Panagopoulos has received honoraria from GILEAD Sciences, Janssen, and MSD. G. N. Dalekos is an advisor or lecturer for Ipsen, Pfizer, Genkyotex, Novartis, Sobi, received research grants from Abbvie, Gilead and has served as PI in studies for Abbvie, Novartis, Gilead, Novo Nordisk, Genkyotex, Regulus Therapeutics Inc, Tiziana Life Sciences, Bayer, Astellas, Pfizer, Amyndas Pharmaceuticals, CymaBay Therapeutics Inc., Sobi and Intercept Pharmaceuticals. E. J. Giamarellos-Bourboulis has received honoraria from Abbott CH, bioMerieux, Brahms GmbH, GSK, InflaRx GmbH, and XBiotech Inc; independent educational grants from Abbott CH, AxisShield, bioMerieux Inc, InflaRx GmbH, Johnson & Johnson and XBiotech Inc.; and funding from the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grants ImmunoSep and RISKinCOVID (granted to the Hellenic Institute for the Study of Sepsis). The other authors do not have any competing interest to declare. Clinical TrialNCT04680949Funding StatementThe trial was sponsored by the Hellenic Institute for the Study of Sepsis (HISS) and funded in part by HISS and in part by Swedish Orphan BioVitrum AB (Sobi).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:approved by the National Ethics Committee of Greece (approval 161/20) and by the Ethics Committee of the National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS in Rome (01.02.2021) (EudraCT number, 2020-005828-11; ClinicalTrials.gov NCT04680949).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAny request should be addressed to the Sponsor-Helleic Institute for the Study of Sepsis (email: insepsis{at}otenet.gr)